Biphasic actions of the adenosine A2a receptor antagonist istradefylline in mice with obstructive uropathy.

ABSTRACT: Regardless of its underlying causes, progressive chronic kidney disease is characterized by progressive kidney fibrosis. The adenosine A2a receptor is expressed by activated kidney fibroblasts. Istradefylline is an adenosine A2a receptor antagonist that has received regulatory authority approval as add-on treatment of Parkinson's disease. Here, we examined the potential of repurposing istradefylline for kidney disease by administering istradefylline to mice with kidney fibrosis caused by unilateral ureteral obstruction (UUO). C57BL/6N mice underwent sham or UUO surgery and were followed for 14 days. Mice were treated with vehicle or istradefylline, with istradefylline initiated either the day after surgery (early intervention) or seven days after surgery (late intervention). Early interven

SUBMITTER: Yeung ESH 

PROVIDER: S-EPMC12635236 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature